Here’s Why Novo Nordisk (NVO) Traded Down in Q3

1 day ago 2

Soumya Eswaran

Wed, December 31, 2025 astatine 7:38 AM CST 3 min read

Chautauqua Capital Management, a part of Baird Asset Management, is simply a boutique concern steadfast that released its 3rd 4th 2025 capitalist missive for the “Baird Chautauqua International and Global Growth Fund”. A transcript of the missive tin beryllium downloaded here. Global equity markets delivered coagulated results successful the 3rd quarter, driven by the solution of important commercialized conflicts and a displacement successful U.S. monetary argumentation toward a much dovish stance. Baird Chautauqua International Growth Fund underperformed the benchmark, MSCI ACWI ex-U.S. Index - ND, successful the quarter, driven by banal enactment successful the accusation technology, financials, and industrials sectors, which detracted the astir from returns. The Baird Chautauqua Global Growth Fund besides trailed the benchmark, MSCI ACWI Index – ND, successful the 4th arsenic banal enactment successful the accusation technology, financials, and industrials sectors detracted the astir from returns. In addition, delight cheque the fund’s apical 5 holdings to cognize its champion picks successful 2025.

In its third-quarter 2025 capitalist letter, Baird Chautauqua International and Global Growth Fund highlighted stocks specified arsenic Novo Nordisk A/S (NYSE:NVO). Novo Nordisk A/S (NYSE:NVO) engages successful the probe and development, manufacture, and organisation of pharmaceutical products. The one-month instrumentality of Novo Nordisk A/S (NYSE:NVO) was 7.99%, and its shares mislaid 40.46% of their worth implicit the past 52 weeks. On December 30, 2025, Novo Nordisk A/S (NYSE:NVO) banal closed astatine $51.22 per share, with a marketplace capitalization of $227.595 billion.

Baird Chautauqua International and Global Growth Fund stated the pursuing regarding Novo Nordisk A/S (NYSE:NVO) successful its 3rd 4th 2025 capitalist letter:

"Novo Nordisk A/S (NYSE:NVO) reported lower-than-expected revenues and net successful a pre-earnings property release, chopped guidance, and announced a CEO alteration 1 week earlier its quarterly net call. The cardinal factors cited are compound proviso overhang and a challenging Ozempic medicine trend. A akin operation of CEO alteration and guidance chopped occurred successful 2016. We judge Novo’s products and pipeline connection amended worth than what is accounted for successful its existent valuation."

Berenberg Lowers Novo Nordisk (NVO) Price Target to DKK 400, Maintains Buy Rating

Novo Nordisk A/S (NYSE:NVO) is not connected our database of 30 Most Popular Stocks Among Hedge Funds. As per our database, 50 hedge money portfolios held Novo Nordisk A/S (NYSE:NVO) astatine the extremity of the 3rd quarter, which was 45 successful the erstwhile quarter. While we admit the imaginable of Novo Nordisk A/S (NYSE:NVO) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.